Live Breaking News & Updates on United Statesi May|Page 1

Stay updated with breaking news from United statesi may. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) | Proteins and Peptides

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) ....

United States , Chandramauli Rawal , Chintu Patel , Kashiv Biosciences , Drug Administration , I Amneal Pharmaceuticals Inc , Company Biologics License Application , United Statesi May , Amneal Pharmaceuticals , Biologics License Application , Co Chief Executive , Chief Operating Officer , Acute Myeloid Leukemia , Therapeutic Protein , Binding Proteins ,

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | DNA RNA and Cells

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma ....

United States , New Jersey , Hermann Einsele , Ying Huang , Janssen Biotech Inc , European Commission , Drug Administration , Medicinal Devices Agency , Julius Maximilian University , European Commission For The Treatment Of Patients , Legend Biotech Corporation , Committee For Orphan Medicinal Products , European Medicines Agency , I Legend Biotech Corporation , Granted Conditional Approval , Refractory Multiple Myeloma , Legend Biotech , European Commission Approved , United Statesi May , Janssen Biotech , Chief Executive Officer , Full Professor , Internal Medicine , Medizinische Klinik , Marketing Authorisation Application , Therapy Designation ,

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Antibodies

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma ....

United States , South Korea , Japan General , I Bristol Myers Squibb , Bristol Myers Squibb , Jaffera Ajani , Adam Lenkowsky , Drug Administration Approves Two Opdivo , National Cancer Institute , American Society Of Clinical Oncology , Bristol Myers Squibb Company , Time Oncology Review Pilot Program , Virtual Congress , American Cancer Society , University Of Texas Md Anderson Cancer Center , Drug Administration , Us Food Drug Administration , Ono Pharmaceutical Co , Based Regimens , First Line Treatments , Unresectable Advanced , Metastatic Esophageal Squamous Cell Carcinoma , United Statesi May , Hazard Ratio , Confidence Interval , Important Safety Information ,

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 | Small Molecules

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 ....

United States , Vickil Goodman , Nabilf Saba , Howard Halpern , American Society Of Clinical Oncology , Neck Cancer Multidisciplinary Program , Emory University , Takeda Pharmaceutical Company , Iexelixis Inc , Neck Cancer Research , Exelixis Inc , Eastern Cooperative Group Performance Status , European Union , Product Development Medical Affairs , Winship Cancer Institute , Exelixis Announces Results , Metastatic Head , Neck Squamous Cell Carcinoma , United Statesi May , Clinical Oncology , Annual Meeting , Oral Abstract Session , Neck Cancer , Response Evaluation Criteria , Solid Tumors , Vice Chair ,

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy | DNA RNA and Cells

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy ....

United States , Rachel Haurwitz , Lorettaj Nastoupil , Jason Obyrne , Steven Kanner , Syed Rizvi , Department Of Lymphoma Myeloma , Caribou Biosciences Inc , University Of Texas Md Anderson Cancer Center , Icaribou Biosciences Inc , European Hematology Association , Messe Wien Exhibition Congress Center , United Statesi May , Messe Wien Exhibition , Congress Center , Friday June , Conference Call Today , Caribou Biosciences , Gene Therapy , Cell Therapy , Stem Cells ,